1. Home
  2. HUMA

as of 01-02-2026 3:53pm EST

$0.97
+$0.02
+2.58%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Founded: 2004 Country:
United States
United States
Employees: N/A City: DURHAM
Market Cap: 236.0M IPO Year: N/A
Target Price: $10.13 AVG Volume (30 days): 4.9M
Analyst Decision: Strong Buy Number of Analysts: 8
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.26 EPS Growth: N/A
52 Week Low/High: $0.91 - $5.48 Next Earning Date: 11-12-2025
Revenue: $1,571,000 Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 698.97%

AI-Powered HUMA Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 3 days ago

AI Recommendation

hold
Model Accuracy: 72.08%
72.08%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: